China Chongqing The third hospital affiliated to the Third Millitary Medical University
Chongqing, Chongqing Municipality, 400042, China
NCT Number: NCT06236698
This is an observational study to define the cut-off value of 24-hour urinary aldosterone for diagnosing primary aldosteronism in hypertensive patients in our center. Plasma aldosterone and renin measurements are subject to significant intra-individual variability, including variation related to posture, time of day and sodium balance. Aldosterone secretion is not constant and may be subject to diurnal variation. As such one-off testing of ARR, does not consider the salt status of the individual necessitating repetition of tests to ensure false negative or false positive test results are ruled out. The value of accumulated aldosterone in a 24-hour sample has the advantage that it does not depend on circadian variation. This study will help establish the positivity rates of 24-hour urine aldosterone, and test the robustness of current standard guidelines for primary aldosteronism screening and case confirmation.
Previous studies reported that primary aldosteronism is associated with a higher risk of CV complications and a higher prevalence of target organ damage. Also, previous studies reported on the association of echocardiographic parameters with circulating or urinary aldosterone. Therefore, we intent to investigate the independent associations of different target organ damage with the urinary excretion of aldosterone.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Chongqing, Chongqing Municipality, 400042, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Collect 24-hour urine sample from each participant and complete the detection of urinary aldosterone content.
Time frame: 2 years
This study will define the cut-off value of 24-hour urinary aldosterone for identifying patients with primary aldosteronism in hypertensive patients.
Time frame: 2 years
Antihypertensive drugs are usually stopped prior to diagnostic testing since they affect the physiological renin-angiotensin-aldosterone system. It is frequently unsafe and impractical to stop taking all conflicting antihypertensive drugs, especially in patients with severe hypertension. The impact of antihypertensive drugs on 24-hour urinary aldosterone, however, has not yet been documented. We tried to investigate how antihypertensive drugs affected 24-hour urine aldosterone levels in this investigation.
Time frame: 2 years
This study will gain futher insight in the association between different target organ damage and the urinary excretion of aldosterone. We will try to find out the reationship between urinary aldosterone and renal function indicators, including eGFR and Urinary microalbumin, and cardiac function indicators, including IVST and PWT.
Zhiming Zhu
Other
Accuracy of 24-hour Urinary Aldosterone Testing in Diagnosing Primary Aldosteronism and Analysis of Drug Interference Factors
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04991961
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Chongqing, Chongqing Municipality, China
View Trial DetailsNCT04269928
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Chongqing, Chongqing Municipality, China
View Trial DetailsNCT03105531
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Uppsala, Uppsla, Sweden
View Trial DetailsNCT03398785
Adrenal Gland Diseases, Adrenocortical Hyperfunction
Chongqing, Chongqing Municipality, China
View Trial Details